2017 International Conference on Malignant Lymphoma

lymphoma

ICML 2017: Nivolumab Shows Durable Response in Relapsed or Progressed Classical Hodgkin Lymphoma, Regardless of Brentuximab Vedotin History

Extended follow-up data demonstrated responses from nivolumab (Opdivo) in adult patients with relapsed or progressed classical Hodgkin lymphoma after autologous stem-cell transplant (ASCT), irrespecti...

leukemia

ICML 2017: Phase III GENUINE Trial: Ublituximab Plus Ibrutinib in High-Risk CLL

Data was recently presented from the phase III GENUINE trial of ublituximab, a novel glycoengineered anti–CD20 monoclonal antibody, in combination with ibrutinib (Imbruvica), a Bruton tyrosine k...

leukemia
lymphoma

ICML 2017: Triplet Combination of Umbralisib, Ublituximab, and Ibrutinib in CLL/SLL/NHL

Data from the chemotherapy-free triple combination of umbralisib, an oral, next generation PI3K delta inhibitor; ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody; and ibrutinib (Imbr...

lymphoma

ICML 2017: Phase II Trial of Tazemetostat in Relapsed or Refractory Follicular Lymphoma and DLBCL

Positive interim efficacy data from an ongoing phase II clinical trial of tazemetostat, a first-in-class, oral enhancer of zeste homolog 2 (EZH2) inhibitor, as a single-agent treatment for relapsed or...

Advertisement

Advertisement



Advertisement